SCHEMBL16770980

SCHEMBL16770980

COCCc1ccc(Cl)cc1Cl

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.62
ALDH1A1 P00352 2/20 0.60
IDO1 P14902 3/20 0.50
MAPK1 P28482 2/20 0.50
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
S1PR4 O95977 2/20 0.45
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
GGPS1 O95749 1/20 0.43
P2RX7 Q99572 1/20 0.43
TRPV1 Q8NER1 1/20 0.43
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
PYCR1 P32322 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24244300 0.87 HTT (0.57) HTTALDH1A1IDO1MAPK1CYP1A2
SCHEMBL12837944 0.85 HTT (0.50) HTTALDH1A1IDO1MAPK1CYP1A2
SCHEMBL20761868 0.82 HTT (0.47) HTTALDH1A1IDO1MAPK1CYP3A4
SCHEMBL20761848 0.81 HTT (0.46) HTTALDH1A1
SCHEMBL11621292 0.80 IDO1 (0.65) HTTIDO1MAPK1CYP1A2CYP3A4
SCHEMBL22519886 0.79 HTT (0.61) HTTALDH1A1IDO1MAPK1CYP1A2
SCHEMBL19129543 0.79 MAPK1 (0.47) HTTALDH1A1IDO1MAPK1CYP1A2
SCHEMBL1989192 0.79 IDO1 (0.64) HTTALDH1A1IDO1MAPK1CYP1A2
SCHEMBL6857573 0.78 IDO1 (0.58) HTTALDH1A1IDO1MAPK1CYP1A2
SCHEMBL13321697 0.77 S1PR4 (0.56) S1PR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170204086-A1 ALPHA-HELIX ANALOG HAVING TRIAZINE-PIPERAZINE BACKBONE AND METHOD FOR PREPARING SAME POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) 2017-07-20 US disclosed
WO-2015078374-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2015-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170204086-A1 ALPHA-HELIX ANALOG HAVING TRIAZINE-PIPERAZINE BACKBONE AND METHOD FOR PREPARING SAME HSPH1, HBZ, PITHD1 HTT 452/4885ALDH1A1 2784/4885IDO1 3581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.